e-learning
resources
Amsterdam 2011
Sunday, 25.09.2011
Bronchodilators in asthma and COPD
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: Results from ATTAIN
A. Agusti, P. W. Jones, E. Bateman, D. Singh, R. Lamarca, G. de Miquel, C. Caracta, E. Garcia Gil (Barcelona, Spain; London, Manchester, United Kingdom; Cape Town, South Africa; , United States Of America)
Source:
Annual Congress 2011 - Bronchodilators in asthma and COPD
Session:
Bronchodilators in asthma and COPD
Session type:
Thematic Poster Session
Number:
874
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Agusti, P. W. Jones, E. Bateman, D. Singh, R. Lamarca, G. de Miquel, C. Caracta, E. Garcia Gil (Barcelona, Spain; London, Manchester, United Kingdom; Cape Town, South Africa; , United States Of America). Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: Results from ATTAIN. Eur Respir J 2011; 38: Suppl. 55, 874
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Respiratory sequelae of preterm birth across the life span
Related content which might interest you:
Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in health status in ATTAIN
Source: Annual Congress 2011 - Bronchodilators in asthma and COPD
Year: 2011
Efficacy of tiotropium bromide in patients with chronic obstructive pulmonary disease of varying severity
Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases II
Year: 2008
The ATTAIN study: Safety and tolerability of aclidinium bromide in chronic obstructive pulmonary disease
Source: Annual Congress 2011 - Airways disease comorbidities and general aspects
Year: 2011
The ATTAIN study: Bronchodilatory effect of aclidinium bromide in chronic obstructive pulmonary disease (COPD)
Source: Annual Congress 2011 - Bronchodilators in asthma and COPD
Year: 2011
Evaluation of the efficacy and safety of two formulations of Ipratropium bromide HFA pMDI in patients with mild to moderate chronic obstructive pulmonary disease (COPD)
Source: Annual Congress 2010 - COPD: treatment and monitoring
Year: 2010
A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease
Source: Eur Respir J 2002; 19: 217-224
Year: 2002
One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease
Source: Eur Respir J 2004; 23: 241-249
Year: 2004
Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease.
Source: Eur Respir J 2003; 21: 912
Year: 2003
Once-daily glycopyrronium improves lung function and reduces exacerbations in severe-to-very severe COPD patients: The SPARK study
Source: Annual Congress 2013 –New bronchodilators for COPD management
Year: 2013
Efficacy of lasolvan in the treatment of patients with chronic obstructive pulmonary disease
Source: Annual Congress 2009 - Drug effects in COPD
Year: 2009
The efficacy of formoterol in patients with chronic obstructive pulmonary disease (COPD) is not influenced by concomitant corticosteroid use
Source: Eur Respir J 2001; 18: Suppl. 33, 515s
Year: 2001
Efficacy of budesonide/formoterol in Chinese patients with chronic obstructive pulmonary disease
Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases II
Year: 2008
Tiotropium in chronic obstructive pulmonary disease: Gender differences in outcomes
Source: International Congress 2016 – Pharmacological management of COPD
Year: 2016
Effects of tiotropium bromide in exercise tolerance in patients with chronic obstructive pulmonary disease
Source: Eur Respir J 2005; 26: Suppl. 49, 289s
Year: 2005
Once-daily QVA149 reduces exacerbations and improves health status in comparison with glycopyrronium and tiotropium in patients with severe-to-very severe COPD: The SPARK study
Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD
Year: 2013
Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease
Source: Eur Respir J 2003; 21: 74-81
Year: 2003
Clinical effectiveness of nebulized budesonide in the treatment of acute asthma and exacerbations of chronic obstructive pulmonary disease (COPD)
Source: Eur Respir J 2001; 18: Suppl. 33, 146s
Year: 2001
Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease
Source: Eur Respir J 2002; 19: 639-644
Year: 2002
Use of bisoprolol: comparison of symptoms worsening in patients with asthma and COPD
Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases
Year: 2008
A trial of beclomethasone/formoterol in COPD using EXACT-PRO to measure exacerbations
Source: Eur Respir J 2013; 41: 12-17
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept